As cited by the research report titled ‘Global Newborn Screening Market Size study, by Technology (Tandem Mass Spectrometry, Pulse Oximetry, Enzyme Based Assays, DNA Assays, Other Technologies), by Test Type (Dried Blood Spot, Hearing Screening, Critical Congenital Heart Defect (CCHD), Other Test Types), by End user (Hospitals, Diagnostic Centers, Other End Users) and Regional Forecasts 2021-2027’, available with Market Study Report, global newborn screening market was worth USD 0.8 billion in 2020 and is projected to grow with a healthy CAGR of 8.3% to accumulate USD 1.4 billion over 2021-2027.
 

Rising prevalence of fetal diseases is compelling healthcare providers to raise awareness among people, which along with demand for innovative screening tools is primarily driving the global newborn screening market growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3891236/
 

Notably, the most common newborn defects like metabolic, hormonal, hearing disorders, and critical congenital heart disease are treatable if detected early, and cognizance about the same is leading to increased demand for newborn screening, thereby propelling the market development.
 

As per the U.S. Centers for Disease Control and Prevention, in the U.S., the prevalence of newborn diseases was 34 per 10,000 live births between the years 2015 and 2017. Every year around 12,900 babies are expected to be diagnosed with a condition. Some other common diseases are congenital hypothyroidism (6.0 per 10,000), hearing deficiency (16.5 per 10,000), sickle-cell disease (4.9 per 10,000), and cystic fibrosis (1.8 per 10,000).
 

Speaking of the negatives, availability of refurbished devices is likely to hinder the market progression over the projected timeline.
 

Based on technology, global newborn screening industry is segmented into pulse oximetry, tandem mass spectrometry, DNA assays, enzyme-based assays, and other technologies. Considering test type, the marketplace is divided into dried blood spot, hearing screening, critical congenital heart defect (CCHD), and other test types. Speaking of end user range, the business space is categorized into hospitals, diagnostic centers, and others.
 

Geographically, Asia Pacific, Europe, North America, and Latin America are the major contributors to the overall industry valuation. Experts cite that, North America is leading the market forecast currently and is poised to showcase lucrative growth trends over the estimated timeline, on account of availability of newborn screening programs, favorable reimbursement policies, and presence of major market players in the region.
 

Meanwhile, Asia Pacific market is likely to account for a massive revenue share over the projected timeframe, owing to increasing screening rate, and growing awareness regarding early disease diagnosis.
 

Prominent players influencing the global newborn screening industry dynamics are Thermo Fisher Scientific, Waters Corporation, Trivitron Healthcare Pvt. Ltd., ZenTech S.A., PerkinElmer Inc., Natus Medical Incorporated, Medtronic plc, Masimo Corporation, GE Healthcare, and Bio-Rad Laboratories Inc.